Syntara Ltd (ASX: SNT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Syntara Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$20.30 million
P/E Ratio
4.64
Dividend Yield
0.00%
Shares Outstanding
1.19 billion
Earnings per share
-0.020
Dividend per share
N/A
Year To Date Return
-15.00%
Earnings Yield
21.54%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Syntara Ltd (ASX: SNT)
Latest News
Share Market News
Why the Pharmaxis (ASX:PXS) share price jumped 6% today
Share Market News
Why the Pharmaxis (ASX:PXS) share price has rocketed up 48% today
Healthcare Shares
ASX stock of the day: Pharmaxis share price surges 8% as milestone payment brought forward
Share Market News
Is the Starpharma share price a buy?
⏸️ Investing
Warning: Every investor should read this before buying speculative biotech companies
⏸️ Investing
This high-risk sector is one ALL new investors should avoid
⏸️ Investing
Revealed: This under-the-radar biotech has blockbuster potential
⏸️ Investing
Here's why Prima Biomed Limited skyrocketed 59% today
⏸️ Investing
Here's why Pharmaxis Ltd. skyrocketed 60% today
⏸️ Investing
Here's why Pharmaxis Ltd. shares are soaring today
⏸️ Investing
6 stocks smashed on the ASX today
⏸️ Investing
4 stocks soaring on the ASX today
1❯
SNT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Syntara Ltd
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
SNT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 26 Apr 2024 | $0.02 | $0.00 | 0.00% | 4,541 | $0.02 | $0.02 | $0.02 |
| 24 Apr 2024 | $0.02 | $0.00 | 0.00% | 5,793,995 | $0.02 | $0.02 | $0.01 |
| 23 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,711,394 | $0.02 | $0.02 | $0.02 |
| 22 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,315,731 | $0.01 | $0.02 | $0.01 |
| 19 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,574,918 | $0.02 | $0.02 | $0.02 |
| 18 Apr 2024 | $0.02 | $0.00 | 0.00% | 2,579,334 | $0.02 | $0.02 | $0.02 |
| 17 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,520,063 | $0.02 | $0.02 | $0.02 |
| 16 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,949,155 | $0.02 | $0.02 | $0.02 |
| 15 Apr 2024 | $0.02 | $0.00 | 0.00% | 3,961,007 | $0.02 | $0.02 | $0.02 |
| 12 Apr 2024 | $0.02 | $0.00 | 0.00% | 7,022,172 | $0.02 | $0.02 | $0.02 |
| 11 Apr 2024 | $0.02 | $0.00 | 0.00% | 7,168,353 | $0.02 | $0.02 | $0.02 |
| 10 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,205,687 | $0.02 | $0.02 | $0.02 |
| 09 Apr 2024 | $0.02 | $0.00 | 0.00% | 127,383 | $0.02 | $0.02 | $0.02 |
| 08 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,272,816 | $0.02 | $0.02 | $0.02 |
| 05 Apr 2024 | $0.02 | $0.00 | 0.00% | 102,647 | $0.02 | $0.02 | $0.02 |
| 04 Apr 2024 | $0.02 | $0.00 | 0.00% | 15,045 | $0.02 | $0.02 | $0.02 |
| 03 Apr 2024 | $0.02 | $0.00 | 0.00% | 3,135,934 | $0.02 | $0.02 | $0.02 |
| 02 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,140,888 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Feb 2024 | Simon Green | Issued | 3,000,000 | $66,000 |
Issue of options.
|
| 13 Feb 2024 | Waradana De Silva | Issued | 3,000,000 | $66,000 |
Issue of options.
|
| 06 Feb 2024 | Simon Green | Issued | 909,091 | $20,000 |
Placement.
|
| 29 Nov 2023 | Gary Phillips | Issued | 2,771,000 | $83,130 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gary Phillips | Chief Executive OfficerManaging Director | Mar 2013 |
Mr Phillips was the Chief Operating Officer since June 2008, having previously served as Commercial Director from his joining of the Company in December 2003. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of a portfolio of new products.
|
| Dr Simon Green | Non-Executive Director | Dec 2022 |
Dr Green has 30 years of experience in the biotechnology industry focussed on the discovery, development and commercialisation of life saving medicines. He worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation prior to joining CSL in 1998. Dr Green was actively involved in CSLs global expansion over a 17 year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSLs manufacturing plants in Germany and Australia
|
| Dr Kathleen Mary Metters | Non-Executive DirectorNon-Executive Chairman | Jun 2017 |
Dr Metters has over 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She is currently working as an independent biopharma consultant, as senior advisor for New York-based Bridge Medicines, as a Non-Executive Director for Aslan Pharmaceuticals Ltd. and an independent board member for HemoShear Therapeutics. From 2011-2014 Dr Metters was President and Chief Executive officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer.
|
| Mr Waradana Malitha Hashan De Silva | Non-Executive Director | Jan 2023 |
Mr De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.
|
| Mr David Morris McGarvey | Company Secretary Chief Financial officer |
-
|
|
| Kristen Morgan | Alliance Management Head of Medical and Regulatory Affairs |
-
|
|
| Jana Baskar | Chief Medical Officer |
-
|
|
| David Morris McGarvey | Company Secretary Chief Financial officer |
-
|
|
| Wolfgang Jarolimek | Head of Drug Discovery |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 147,191,348 | 20.38% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 108,361,494 | 15.01% |
| Hsbc Custody Nominees (Australia) Limited | 73,020,165 | 10.11% |
| D and A Income Limited | 38,690,477 | 5.36% |
| Lawn Views Pty Ltd <Angela Williams Family A/C> | 10,350,966 | 1.43% |
| Dr Toby David Cohen | 6,749,457 | 0.93% |
| Bnp Paribas Noms Pty Ltd <Drp> | 6,487,405 | 0.90% |
| Healthcare Management Consulting (Australia) Pty Ltd | 5,262,950 | 0.73% |
| Mr David Curzon Smith and Mrs Diane Maurine Smith <Badham Family A/C> | 4,255,715 | 0.59% |
| Ms Bei Xu and Mr Dongning Wu | 3,600,891 | 0.50% |
| Indcorp Consulting Group Pty Limited <Superannuation Fund A/C> | 3,000,001 | 0.42% |
| Mr Xing Jiang Xue | 2,729,886 | 0.38% |
| Finter Nominees Pty Ltd <TJF Family A/C> | 2,700,000 | 0.37% |
| Pakasoluto Pty Limited <Barkl Family Super Fund A/C> | 2,622,007 | 0.36% |
| Mr Peter John Carr | 2,510,000 | 0.35% |
| Bnp Paribas Nominees Pty Ltd Acf Clearstream | 2,503,208 | 0.35% |
| Bunyula Super Pty Ltd <Bunyula Super Fund A/C> | 2,477,076 | 0.34% |
| Mr Joseph Wallace Carson | 2,476,192 | 0.34% |
| Mr Gregory Bruce Cole and Mrs Julia Theresa Cole <Greg & Julie Super Fund A/C> | 2,430,000 | 0.34% |
| Mrs Sharon Lewis | 2,265,715 | 0.31% |
